Scopolamine (hyoscine) for preventing and treating motion sickness

Motion sickness: A cholinomimetic agent hypothesis

“…It has been suggested that parasympathetic activation may be responsible for much of the stomach emptying behavior in motion sickness, and also that sympathetic nervous system activity potentially provides a protective effect [9,25,50]. These assertions are consistent with the observation that motion sickness can be treated and to some degree prevented by the administration of both anticholinergic and adrenergic medications; parasympathetic blockers and sympathetic stimulants respectively [9,31,42,51]. However, the time course and pattern of the autonomic response to motion sickness has not been fully explained.…”

Motion sickness: A cholinomimetic agent hypothesis

“…It has been suggested that parasympathetic activation may be responsible for much of the stomach emptying behavior in motion sickness, and also that sympathetic nervous system activity potentially provides a protective effect [9,25,50]. These assertions are consistent with the observation that motion sickness can be treated and to some degree prevented by the administration of both anticholinergic and adrenergic medications; parasympathetic blockers and sympathetic stimulants respectively [9,31,42,51]. However, the time course and pattern of the autonomic response to motion sickness has not been fully explained.…”

Motion Sickness: Current Knowledge and Recent Advance

“…Atropine, scopolamine (hyoscine), and hyoscyamine have already been used to treat MS before World War I. A recent cochrane systematic review of 14 randomized controlled trials (RCTs) concluded that scopolamine, the nonselective muscarinic cholinergic receptor (mAChR) antagonist, was more effective than placebo but not superior to antihistamines in preventing MS and was no more likely to induce drowsiness, blurring vision, or dizziness compared to other agents . Nevertheless, the precise mAChR subtypes (M 1 –M 5 ) that serve as the targets of scopolamine is still unclear.…”

Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling

“…Signaling through mAChRs affects a wide spectrum of diseases, and hence, many mAChR antagonists are already approved in the United States for use in people. Among these are atropine for childhood myopia ( 73 ) and scopolamine for motion sickness ( 74 ). Unfortunately, these agents have very short half-lives in vivo and are thereby not suitable for cancer studies.…”

Motion sickness: A cholinomimetic agent hypothesis

“…It has been suggested that parasympathetic activation may be responsible for much of the stomach emptying behavior in motion sickness, and also that sympathetic nervous system activity potentially provides a protective effect [9,25,50]. These assertions are consistent with the observation that motion sickness can be treated and to some degree prevented by the administration of both anticholinergic and adrenergic medications; parasympathetic blockers and sympathetic stimulants respectively [9,31,42,51]. However, the time course and pattern of the autonomic response to motion sickness has not been fully explained.…”

Motion Sickness: Current Knowledge and Recent Advance

“…Atropine, scopolamine (hyoscine), and hyoscyamine have already been used to treat MS before World War I. A recent cochrane systematic review of 14 randomized controlled trials (RCTs) concluded that scopolamine, the nonselective muscarinic cholinergic receptor (mAChR) antagonist, was more effective than placebo but not superior to antihistamines in preventing MS and was no more likely to induce drowsiness, blurring vision, or dizziness compared to other agents . Nevertheless, the precise mAChR subtypes (M 1 –M 5 ) that serve as the targets of scopolamine is still unclear.…”

Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling

“…Signaling through mAChRs affects a wide spectrum of diseases, and hence, many mAChR antagonists are already approved in the United States for use in people. Among these are atropine for childhood myopia ( 73 ) and scopolamine for motion sickness ( 74 ). Unfortunately, these agents have very short half-lives in vivo and are thereby not suitable for cancer studies.…”

Motion sickness: A cholinomimetic agent hypothesis

“…It has been suggested that parasympathetic activation may be responsible for much of the stomach emptying behavior in motion sickness, and also that sympathetic nervous system activity potentially provides a protective effect [9,25,50]. These assertions are consistent with the observation that motion sickness can be treated and to some degree prevented by the administration of both anticholinergic and adrenergic medications; parasympathetic blockers and sympathetic stimulants respectively [9,31,42,51]. However, the time course and pattern of the autonomic response to motion sickness has not been fully explained.…”

Motion Sickness: Current Knowledge and Recent Advance

“…Atropine, scopolamine (hyoscine), and hyoscyamine have already been used to treat MS before World War I. A recent cochrane systematic review of 14 randomized controlled trials (RCTs) concluded that scopolamine, the nonselective muscarinic cholinergic receptor (mAChR) antagonist, was more effective than placebo but not superior to antihistamines in preventing MS and was no more likely to induce drowsiness, blurring vision, or dizziness compared to other agents . Nevertheless, the precise mAChR subtypes (M 1 –M 5 ) that serve as the targets of scopolamine is still unclear.…”

Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling

“…Signaling through mAChRs affects a wide spectrum of diseases, and hence, many mAChR antagonists are already approved in the United States for use in people. Among these are atropine for childhood myopia ( 73 ) and scopolamine for motion sickness ( 74 ). Unfortunately, these agents have very short half-lives in vivo and are thereby not suitable for cancer studies.…”